An understanding of the antibody persistence elicited by a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliovirus vaccine (Tdap-IPV) after adolescent vaccination is important to optimize booster dosing intervals. Our objectives were to compare the safety and immunogenicity of Tdap-IPV coadministered with hepatitis B vaccine (HepB) and sequential administration and evaluate humoral immunity at 3, 5, and 10 years after Tdap-IPV vaccination in adolescents. This phase II randomized, controlled, and open-label study enrolled 280 11-to 14-year-old adolescents with up to 10 years postvaccination follow-up. Group 1 (n ‫؍‬ 145) received Tdap-IPV, followed by a HepB dose 1 month later, and group 2 (n ‫؍‬ 135) received both vaccines simultaneously. No consistent increases in solicited reactions or unsolicited adverse events occurred with coadministration. All vaccinees attained seroprotective antibody levels at >0.01 IU/ml for diphtheria and tetanus, at a >1:8 dilution for poliovirus (serotypes 1, 2, and 3), and >10 mIU/ml for hepatitis B at 1 month postvaccination. Clinically relevant immunologic interactions did not occur with coadministration. For pertussis, all participants achieved seropositivity levels (at or above the lower limit of quantitation), and 72.7% to 95.8% had 4-fold increases in pertussis antibodies at 1 month postvaccination. At 10 years postvaccination, the remaining participants (62.8% of the original cohort) maintained seroprotective levels of >0.01 IU/ml for diphtheria and tetanus, a >1:8 dilution for all 3 poliovirus serotypes, and 74.1% to 98.2% maintained pertussis seropositivity levels depending on the antigen tested. There were no differences between the groups. These results support the coadministration of Tdap-IPV and HepB to adolescents and suggest that vaccination with Tdap-IPV can offer protection for 10 years after an adolescent booster vaccination.
D
espite widespread childhood immunization with pertussis vaccines, the recurrence of pertussis has been reported among adolescents and young adults, with periodic outbreaks in several countries, suggesting early waning of immunity (1) (2) (3) (4) (5) (6) (7) (8) . In these outbreaks, high rates of pertussis infection were observed among infants age Ͻ1 year, and the incidence in adolescents age 10 to 14 years also increased.
In addition to pertussis morbidity in infected adolescents and adults, these patients constitute a major source of transmission to infants, especially those Ͻ6 months of age, who are at highest risk for serious disease and death (3, 9) . Thus, pertussis immunization of adults and adolescents is recommended for both personal protection and to reduce exposure in vulnerable infants (10, 11) . The current recommendations for adolescent vaccination in some European countries and most Canadian provinces include combined tetanus, diphtheria, and acellular pertussis (Tdap) and hepatitis B (HepB) vaccines (12) . In Canada, the incidence of reported pertussis decreased in all age groups after the National Advisory Committee on Immunization (NACI) recommended the inclusion of a tetanus-diphtheria-acellular pertussis (Tdap) booster for adolescents 14 to 16 years of age (12) .
Long-term antibody persistence information after adolescence Tdap vaccination has become available in recent years (13) (14) (15) (16) (17) (18) (19) (20) . In general, antibody levels are highest at 1 month postvaccination and decrease over time (13) (14) (15) 17) ; by 10 years postvaccination, antibody concentrations return to levels comparable to or approaching those observed before vaccination (19) .
One strategy for improving health care for adolescents and young adults is vaccination programs targeting vaccine-preventable illnesses they are at high risk of acquiring. The coadministration of the Tdap combination vaccine with the HepB vaccine in early adolescence would facilitate more cost-effective adolescent vaccination strategies. It would also help attain immunization target levels by decreasing the number of health care visits needed to complete vaccination schedules. Long-term humoral immunity follow-up assessments may help select optimal dosing intervals for future booster vaccinations after adolescence. The objective of this study was to determine the safety and immunogenicity of a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliovirus vaccine (Tdap-IPV), followed by a dose of HepB vaccine 1 month later, compared with the Tdap-IPV and HepB vaccines administered concurrently in adolescents 11 to 14 years of age, and to evaluate humoral immunity at 3, 5, and 10 years after Tdap-IPV vaccination.
MATERIALS AND METHODS
Study design. This was a phase II, open-label, randomized, and controlled study conducted at the University of Manitoba, Manitoba, Canada, with vaccinations conducted between January 1999 and May 2000. The study was approved by the University of Manitoba ethics committee; signed and witnessed informed consent was obtained from the parents or legal guardians of the participants prior to the first study intervention.
Randomization was performed by the trial statistician and staff, who were not involved in the clinical aspects of the trial. Assignment to group 1 or 2 was performed at a 1:1 ratio via telephone at the time of consent. Group 1 received Tdap-IPV, followed by HepB approximately 1 month later. Group 2 received Tdap-IPV and HepB concurrently. In both groups, the second and third doses of HepB were given 1 month and 6 months after the initial HepB vaccination. All participants kept daily diaries and were assessed by the study team for safety for 2 weeks. For immunogenicity, the participants had blood draws immediately before vaccination, 1 month after Tdap-IPV (with or without HepB) vaccination, and 1 month after the last HepB dose to measure hepatitis B antibody levels. All participants were contacted and asked to return for additional blood draws and subsequent Tdap-IPV serology testing at 3, 5, and 10 years postvaccination, in 2002, 2004, and 2009, respectively. HepB serology was not performed at the subsequent time points, as the follow-up was designed to be an open-label long-term assessment of the persistence of Tdap-IPV vaccine-elicited antibodies.
Participants. At study entry, the participants were 11 to 14 years of age and in good health based on their reported medical history. The exclusion criteria included immunodeficiency, immunosuppression, or receipt of high-dose steroids; any substantial underlying chronic disease, including malignancy; known impairment in neurologic function or a seizure disorder of any etiology; known or suspected allergy to any vaccine components in the study; receipt of any pertussis-, diphtheria-, tetanus-, or poliomyelitis-containing vaccines or HepB vaccine within the previous 5 years; history of physician-diagnosed or laboratory-confirmed pertussis disease within the previous 2 years; receipt of blood products or immunoglobulins within the previous 3 months; receipt of any vaccine within 2 weeks of any study vaccine administration; or daily use of nonsteroidal anti-inflammatory drugs (NSAIDs). To ensure that the follow-up populations were representative of the original study participants in terms of immunogenicity, baseline immunogenicity measurements with respect to prevaccination and 1 month postvaccination were assessed for all vaccine antigens for the participants at each follow-up period. For the long-term follow-up, the participants who were diagnosed with pertussis or received any tetanus-diphtheria (Td) or Tdap vaccine after the study vaccine were excluded from analysis.
Vaccines. Both vaccines required intramuscular administration with a needle of Ն25 mm (1 in.). A single 0.5-ml dose of the Tdap vaccine with inactivated poliomyelitis vaccine (Tdap-IPV; Adacel-Polio) contained tetanus (5 flocculation units [Lf] ) and diphtheria (2 Lf) toxoids adsorbed Serological assays. The serological assays were performed by Sanofi Pasteur. The Global Clinical Immunology Laboratory (GCI) (USA) performed the diphtheria and tetanus assays on the 5-year samples and all assays on the 10-year samples. The Clinical Immunology Platform Canada (CIP-CA) performed all baseline, 1-month, and 3-year postvaccination assays, as well as the pertussis assays of the 5-year samples. All assays were determined to be concordant between the laboratories, or adjustment factors were used to make the data concordant.
The prevaccination and 1-month postvaccination serum samples were assayed in parallel; the follow-up serum samples were assayed separately shortly after collection at the 3-, 5-, and 10-year sampling times. The anti-tetanus antibody concentrations were measured by enzyme-linked immunosorbent assay (ELISA) and expressed as international units (IU)/ ml. The diphtheria antibody responses were measured by microneutralization assay and expressed as IU/ml. The antibody titers to poliovirus serotypes 1, 2, and 3 were measured by a microneutralization assay and expressed as the inverse serum dilution able to neutralize 50% of the challenge virus. The antibody levels to PT, FHA, PRN, and FIM were measured by ELISA and expressed in ELISA units (EU)/ml. Because there are no universally accepted correlates of pertussis protection, seropositivity was evaluated by determining the proportion of participants with antibody levels at or above the lower limit of quantitation (LLOQ) (23) . For the assays performed at CIP-CA, the LLOQs were 5 EU/ml for PT, 3 EU/ml for FHA, 3 EU/ml for PRN, and 17 EU/ml for FIM; for the assays performed at GCI, the LLOQs were 4 EU/ml for PT, PRN, and FIM, and 3 EU/ml for FHA; the seropositivity results are expressed using the LLOQ of the relevant laboratory. Antibodies to HBsAg were measured by a radioimmunoassay only as part of the original study and expressed as mIU/ml. Safety endpoints. The safety endpoints and related periods of follow-up postvaccination were as follows: the rates of solicited injection site reactions (pain, erythema, swelling, and axillary lymph node swelling) and solicited systemic reactions (fever, chills, headache, generalized body ache and/or muscle weakness, tiredness and/or decreased energy, nausea, vomiting, diarrhea, and sore and/or swollen joints) at 0 to 24 h, 24 to 72 h, and 3 to 14 days; the rates of immediate reactions within 30 min; unsolicited adverse events (AEs) spontaneously reported within 14 days after Tdap-IPV injection; and serious adverse events (SAEs) at any time during the study through 30 days after the last vaccination. The intensities of the solicited local and systemic reactions were classified as mild, moderate, or severe based on magnitude (mild, Ͻ10 mm; moderate, 10 to 34 mm; severe, Ͼ35 mm of redness or swelling) and the degree of interference with daily activities was assessed for the systemic AEs. Orally measured fever was classified as mild (38.0°C to 38.9°C), moderate (39.0°C to 39.9°C), or severe (Ն40°C). Moderate and severe AEs were grouped together in the analysis.
Immunogenicity endpoints. Immunogenicity was measured by the proportion of participants achieving seroprotective levels of antibodies of Ն0.01 IU/ml and 0.1 IU/ml for diphtheria and tetanus, respectively, and a Ն1:8 dilution for poliovirus. For pertussis, the rates of a 4-fold increase in antibody levels were calculated at 1 month postvaccination. To examine the immunologic interactions between Tdap-IPV and HepB, the geometric mean titers (GMTs) of antibodies and the corresponding seroprotection rates achieved for each Tdap-IPV antigen (not shown for pertussis) were compared. For the HepB vaccine, immunogenicity was measured by the proportion of participants attaining levels of Ն10 mIU/ml, the seroprotective hepatitis B antibody level.
The immunogenicity endpoints for all Tdap-IPV antigens were also evaluated at 3, 5, and 10 years postvaccination, as described above. The pertussis antibody levels were assessed against the LLOQ, in which antibody levels at or above the LLOQ were considered seropositive.
Statistical analysis. A sample size of 140 participants per treatment arm was calculated to provide 90% power at a two-sided significance level of 5% to detect a difference in the treatment arms of 15% and allow for a 10% dropout rate. The intended sample size was determined based on antibody responses to pertussis antigens in prior studies using the twosided equivalence approach for the difference in two proportions (24) .
No formal hypothesis was tested, and no statistical testing was performed in this study. The safety endpoints were summarized as the number and percentage of participants with a solicited reaction or unsolicited AE tabulated by intensity and study group. The differences in the response rates between the groups with 90% confidence intervals (CIs) were calculated for each AE at each time point. The solicited AEs were considered clinically equivalent if the confidence interval on the difference in the rates between the groups was within Ϫ15% to ϩ15%. For the immunogenicity endpoints, continuous variables were presented by summary statistics (mean, standard deviation [SD], and GMTs with 95% CI) and categorical variables by frequency distributions (counts and percentages). The differences in anti-diphtheria, anti-tetanus, and anti-poliovirus seroprotection rates, as well as pertussis 4-fold increases, were calculated with 90% CIs (data not shown). For pertussis in the long-term follow-up, seropositivity (at or above the LLOQ) was presented by descriptive statistics.
All participants who received the study vaccine and had Ն1 valid postvaccination safety or immunogenicity evaluation were included in the intent-to-treat (ITT) analysis set and analyzed for safety and immunogenicity. All participants without a protocol deviation were included in the per-protocol (PP) analysis set for immunogenicity analyses.
RESULTS

Participants.
Healthy participants (n ϭ 280) were randomized to group 1 (n ϭ 145) or group 2 (n ϭ 135). Nine participants dropped out the study before completion (Fig. 1) . The groups Safety results. Overall, the rates of AEs were comparable between the groups. No vaccination-related serious AEs (SAEs) were reported, and no safety concerns were identified. No consistent increases in solicited reactions or unsolicited AEs were reported when Tdap-IPV and HepB were coadministered.
Solicited reactions. Most solicited local reactions at the Tdap-IPV injection site were mild and occurred within 0 to 24 h postvaccination (Table 1) . Pain was the most frequently reported local reaction at 0 to 24 h and was reported by almost all participants. In the 24-to 72-h interval, the reports of pain at the Tdap-IPV injection site were higher in group 1 (58.3%) than in group 2 (50.8%). By 3 to 14 days, the frequency of pain reports had diminished equally in the two groups. Similar trends were observed for redness and swelling. Axillary lymph node swelling was most frequently reported within 24 to 72 h. Overall, the local AE rates at the Tdap-IPV injection site were comparable between the groups.
The solicited systemic reactions were mostly mild and more commonly reported in both groups in the first 24 h ( Table 2 ). The most frequent reports in the first 24 h were for body ache/muscle weakness and tiredness. At 24 to 72 h, the frequency of systemic AE reports decreased in both groups (ranging from 0% for vomiting to a maximum of 23.5% for headaches and tiredness in group 2). At 3 to 14 days, there was an apparent increase in the rates of headache, diarrhea, nausea, and vomiting reports (ranging from 2.3% for vomiting in group 2 to 40.3% for headaches in group 1). These events were equally distributed between the groups and were not considered to be directly related to vaccination. Fever reports were rare in both groups, with 3 in each group within 0 to 24 h, and 4 in group 1 and 2 in group 2 within 24 to 72 h. The rates of solicited systemic reactions were numerically similar in the two groups.
Unsolicited AEs. Unsolicited AEs were reported by approximately 60% of the participants, with comparable reporting rates of 61.8% in group 1 and 58.3% in group 2. Most unsolicited AEs were mild, with onset in the first days after vaccination, and were reported to be unrelated to the study vaccine. These reports were not coded; however, the most common AEs reported were cold symptoms/flu-like syndrome, followed by stomachache. Unsolicited AEs reported to be definitely related to vaccination were also equally distributed between groups 1 and 2 (8 per group).
Serious adverse events. Four SAEs were reported; all required hospitalization, and none were considered to be vaccination related. One participant from each group experienced a fracture (at 7 days postvaccination for one participant and 29 days postvaccination for the other [third HepB dose]). In addition, a group 2 participant experienced appendicitis at 11 days after the first dose of HepB and Tdap-IPV, and a diabetic group 2 participant experienced viral gastroenteritis and unstable glycemia at 3 months after the second dose of HepB. Immunogenicity. At 1 month postvaccination, the seroprotection rates against diphtheria, tetanus, and poliomyelitis were comparable between the groups (Tables 3 and 4) ; all reached seroprotective antibody levels of Ն0.01 IU/ml for diphtheria and tetanus, a Ն1:8 dilution for poliovirus types 1, 2, and 3, and Ն10 mIU/ml for hepatitis B. All participants achieved levels of Ն0.1 IU/ml for tetanus. For diphtheria, 98.6% of the group 1 participants and 100% of the group 2 participants achieved seroprotective levels of Ն0.1 IU/ml.
The pertussis antibody seroresponses 1 month after Tdap-IPV vaccination were comparable between groups 1 and 2, as measured by 4-fold increases in PT (88.7% versus 86.4% for groups 1 and 2, respectively), FHA (76.6% versus 72.7%, respectively), FIM (88.7% versus 90.8%, respectively), and PRN (95.8% versus 87.9%, respectively). No clinically relevant interference was observed with Tdap-IPV and HepB coadministration.
Antibody geometric mean titers. Although high prevaccination tetanus, diphtheria, and poliovirus antibody levels were observed, the GMTs rose after vaccination, indicating a booster response ( Table 5 ). The tetanus and diphtheria GMTs at 1 month after Tdap-IPV vaccination were comparable whether the vaccine was given alone or with a dose of HepB. The poliovirus GMTs achieved were high (Table 5) .
Antibody persistence. Long-term antibody persistence was evaluated from blood samples taken 3, 5, and 10 years after Tdap-IPV vaccination. The immunogenicity profiles were comparable between the groups for all endpoints and at all time points. For diphtheria, tetanus, and poliomyelitis, the seroprotection rates remained high for up to 10 years postvaccination (Tables 3 and 4) . At 10 years, 100% of the participants had anti-diphtheria antibody levels of Ն0.01 IU/ml, while 85.9% (group 1, 88.4%; group 2, 82.9%) maintained levels of Ն0.1 IU/ml, which is adequate for long-term protection (25) . For tetanus, 100% of the participants maintained levels of Ն0.01 IU/ml at 10 years, while 98.7% (group 1, 100%; group 2, 97.1%) maintained levels of Ն0.1 IU/ml. All participants maintained poliovirus seroprotective levels of a Ն1:8 dilution for all 3 poliovirus types at all postvaccination time periods.
After substantial increases at 1 month after vaccination, the anti-diphtheria, anti-tetanus, and anti-poliovirus GMTs declined during the first 3 years (Table 5) . At 10 years, the diphtheria and tetanus GMTs had returned to prevaccination levels. The antipoliovirus GMT levels declined over time but remained above the prevaccination levels for all 3 poliovirus types ( Table 5 ). The antipertussis GMTs declined over time, with the largest decrease occurring in the first years postvaccination (Fig. 2) .
Pertussis seropositivity was defined as being at or above the LLOQ for the follow-up time points, and at 1 month postvaccination, 100% of the participants had detectable antibodies for each pertussis antigen (Table 6 ). The antibodies persisted at levels higher than those at prevaccination at 5 years postvaccination, but they returned to those levels after 10 years for PT and FHA (Fig. 2) . The anti-PRN and anti-FIM antibody levels at 10 years postvaccination were still above the prevaccination levels. PT had the lowest percentage of participants with detectable antibodies after 10 years (74.1%); the percentages of other three antigens were higher (96.5% to 98.2%).
The results for the immunogenicity outcomes were similar between the ITT and PP populations.
DISCUSSION
Tdap-IPV is approved in numerous countries around the world as a booster vaccine in persons Ն3 years of age. This study examined the coadministration of Tdap-IPV with HepB in adolescents and the persistence of Tdap-IPV antibodies for up to 10 years. The solicited AE rates were generally comparable to those observed in adolescents and adults who were vaccinated with a single dose of a Tdap or Tdap-IPV vaccine (26) . The AE rates were comparable between the study groups. There were no consistent increases in the rates of solicited reactions or unsolicited AEs when Tdap-IPV and HepB were coadministered at separate injection sites, except for pain reports at 24 to 72 h postvaccination. One month after the Tdap-IPV vaccination, the immune responses to all antigens were robust.
The long-term immunogenicity results from this study are consistent with the results from a pooled analysis of 10-year immunogenicity data from three clinical trials conducted in adolescents and adults (19) . In that analysis, 99.3% of the adolescents had protective levels of antibodies against diphtheria and tetanus and seropositivity to Ն1 pertussis antigens 10 years after their booster dose of Tdap. The adolescents in one of the studies included in the pooled analysis also received the HepB vaccine, which did not appear to affect the immunogenicities of diphtheria, tetanus, and pertussis, similar to the results presented here.
While pertussis protective levels have not yet been clearly defined, previous publications have defined minimal long-term protective levels as those that are greater than the LLOQ value (14, 27) . For all pertussis antigens at 1 month postvaccination, all participants achieved antibody levels that were at or above the LLOQ; at 10 years postvaccination, between 74.1% and 98.2% of the participants (2 groups combined) maintained detectable antibody levels. Further, all vaccinees maintained seroprotective levels for diphtheria, tetanus, and all 3 poliovirus serotypes at 10 years after Tdap-IPV administration. Thus, the long-term antibody profile suggests that seroprotection against diphtheria, tetanus, and poliomyelitis is maintained for Ն10 years after booster adolescent vaccination. The study had some limitations. The study was powered to evaluate immunogenicity, and so rare AEs or SAEs may not have been detected. Safety was assessed for 14 days after each vaccination (except for SAEs, which were collected at any time through 30 days after the last vaccination) but this information was not collected throughout the 10-year follow-up. Only 62.8% of the participants could be assessed at the 10-year follow-up, and not all participants could be assessed at all time points. The determination of prior exposure to pertussis disease or pertussis vaccination was based on participant recall only and was not verified from medical records.
When given alone or concurrently with HepB, the results demonstrated that Tdap-IPV is safe and immunogenic in 11-to 14-year-old adolescents. Clinically relevant immunologic interactions did not occur when Tdap-IPV and HepB were given concurrently, which provides evidence for a recommendation that the vaccines be administered simultaneously. This strategy would eliminate the need for an additional medical visit and facilitate cost-effective vaccination. This approach would also improve the ability of immunization programs to meet the target goals for vaccine coverage.
